157 reports of this reaction
2.7% of all PREDNISOLONE SODIUM PHOSPHATE reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for PREDNISOLONE SODIUM PHOSPHATE, manufactured by Advanz Pharma (US) Corp.. There are 157 FDA adverse event reports linking PREDNISOLONE SODIUM PHOSPHATE to OFF LABEL USE. This represents approximately 2.7% of all 5,859 adverse event reports for this drug.
Patients taking PREDNISOLONE SODIUM PHOSPHATE who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for PREDNISOLONE SODIUM PHOSPHATE, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for PREDNISOLONE SODIUM PHOSPHATE:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 157 FDA reports for PREDNISOLONE SODIUM PHOSPHATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 2.7% of all adverse event reports for PREDNISOLONE SODIUM PHOSPHATE, making it one of the most commonly reported side effect.
If you experience off label use while taking PREDNISOLONE SODIUM PHOSPHATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.